Heino Stöver

Heino Stöver

Auto-generated profile, based on publicly available information

Heino Stöver

Frankfurt University of Applied Sciences

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2016 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
Daniel DeimelDaniel Deimel
Daniel Deimel
HSHeino Stöver
Heino Stöver
SHSusann Hößelbarth
Susann Hößelbarth
ADAnna Dichtl
Anna Dichtl
NGNiels Graf
Niels Graf
VGViola Gebhardt
Viola Gebhardt
Men who have sex with men (MSM) are a risk group for new HIV infections. Drug use among men who have sex with men is often accompanied by risky sexual behaviours. Local AIDS help centres and gay advice centres are recording an increase in drug use among MSM clients in Germany. This study examines reasons for drug use and drug use contexts for MSM, including syndemic factors and experiences of social support. The study is based on a qualitative research approach. We conducted 14 structured, in-depth interviews with substance-using MSM in three German cities. An interview guidance document was used that was developed on the basis of the syndemic approach. Data analysis was based on structured analysis of content. The MSM interviewed had extensive experience of drug use, in particular amyl nitrate, amphetamines, methamphetamine, ketamine, cocaine and cannabis. The drugs were used both at parties and in connection with sexual experiences (chemsex). Twelve men said that they had an existing HIV infection at the time of the interview. The men also reported experiences of violence and discrimination because of their sexual orientation. The social networks of the MSM and dating apps are highly relevant for experiencing chemsex. Certain places in the MSM community also have an impact on drug purchase, drug consumption and chemsex sessions. MSM are a group that is vulnerable to psychological problems, in particular problematic drug use. This group requires specific help from drug services and AIDS support services that are orientated towards the life situation and substance use contexts of the clients. Both support systems should work together more closely and network. Furthermore, specific prevention strategies, aimed at both mental and physical well-being, should be developed for substance-using MSM.

8 January 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
HSH. Stöver
H. Stöver
FMF. Meroueh
F. Meroueh
AMAndrés Marco
Andrés Marco
KKK. Keppler
K. Keppler
PHP. Saiz de la Hoya
P. Saiz de la Hoya
LSLorenzo Somaini
Lorenzo Somaini
Prisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-acting antiviral products with superior efficacy and safety compared to interferon-based regimens offer HCV cure. Many citizens in Europe have been treated, although few received therapy in prisons. Analysis of prisoner HCV treatment need and policy determinants of clinical practice was completed for 5 EU countries. Evidence was collected from national statistical sources and peer-reviewed publications to describe prison populations and HCV prevalence, to map national prison/ HCV health policy or guidance. A consensus of important principles for prisoner HCV care was developed. Data from published sources describing prisoner HCV prevalence is limited. Prisoner population requiring HCV treatment is not known; estimated numbers based on analysis of evidence: England and Wales, 9000, France, 8000, Spain, 6000, Italy, 6000, Germany, 6000. Treatment access: national law defines right to equivalent care in all countries implying access to HCV therapy in prison similar to community; useful prisoner HCV guidance facilitating treatment decisions present in: 4 of 5 national/ regional HCV policy documents, 4 of 5 national prison healthcare policies. Four of five had practical prison HCV clinical guidelines. Despite existence of policy, implementation of guidance, and so HCV treatment, is suboptimal in many locations. Prison is an important location to detect, address and treat HCV infection in people who may be underserved for healthcare and find it difficult to navigate community treatment pathways. This is often related to problems with OUD and resulting social inequity. HCV management in prisons must be improved. Policy and clinical practice guidance must be set to promote treatment, and practical steps to make treatment easy should be followed including education to promote engagement, set-up of optimal screening and work up processes with modern tools to reduce time needed/ achieve efficiency; programs to make it easier to get specialists’ input include remote working and nurse-led services.

11 May 2018 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
RBRob Bielen
Rob Bielen
SSSamya R. Stumo
Samya R. Stumo
RHRachel Halford
Rachel Halford
KWKlára Werling
Klára Werling
TRTatjana Reic
Tatjana Reic
JLJeffrey Lazarus
Jeffrey Lazarus
Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although harm reduction services such as opioid substitution therapy (OST) and needle and syringe programs (NSPs) are effective in preventing the further spread of HCV and HIV, the extent to which these are available in prisons varies significantly across countries. The Hep-CORE study surveyed liver patient groups from 25 European countries in 2016 and mid-2017 on national policies related to harm reduction, testing/screening, and treatment for HCV in prison settings. Results from the cross-sectional survey were compared to the data from available reports and the peer-reviewed literature to determine the overall degree to which European countries implement evidence-based HCV recommendations in prison settings. Patient groups in nine countries (36%) identified prisoners as a high-risk population target for HCV testing/screening. Twenty-one countries (84%) provide HCV treatment in prisons. However, the extent of coverage of these treatment programs varies widely. Two countries (8%) have NSPs officially available in prisons in all parts of the country. Eleven countries (44%) provide OST in prisons in all parts of the country without additional requirements. Despite the existence of evidence-based recommendations, infectious disease prevention measures such as harm reduction programs are inadequate in European prison settings. Harm reduction, HCV testing/screening, and treatment should be scaled up in prison settings in order to progress towards eliminating HCV as a public health threat.

29 June 2021 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
HSHeino Stöver
Heino Stöver
ATAnna Tarján
Anna Tarján
GHGergely Horváth
Gergely Horváth
LMLinda Montanari
Linda Montanari
Background: People who inject drugs are often imprisoned, which is associated with increased levels of health risks including overdose and infectious diseases transmission, affecting not only people in prison but also the communities to which they return. This paper aims to give an up-to-date overview on availability, coverage and policy framework of prison-based harm reduction interventions in Europe. Methods: Available data on selected harm reduction responses in prisons were compiled from international standardised data sources and combined with a questionnaire survey among 30 National Focal Points of the European Monitoring Centre for Drugs and Drug Addiction to determine the level of availability, estimated coverage and policy framework of the interventions. Results: Information about responses to health harms in prisons is limited and heterogeneous. Cross-country comparability is hampered by diverging national data collection methods. Opioid substitution treatment (OST) is available in 29 countries, but coverage remains low (below 30% of people in need) in half of the responding countries. Needle and syringe programmes, lubricant distribution, counselling on safer injecting and tattooing/piercing are scarcely available. Testing for infectious diseases is offered but mostly upon prison entry, and uptake remains low in about half of the countries. While treatment of infections is mostly available and coverage is high for human immunodeficiency virus (HIV) and tuberculosis, hepatitis B and C treatment are less often provided. Health education as well as condom distribution is usually available, but provision remains low in nearly half of the countries. Post-release linkage to addiction care as well as to treatment of infections is available in a majority of countries, but implementation is often partial. Interventions recommended to be provided upon release, such as OST initiation, take-home naloxone and testing of infections, are rarely provided. While 21 countries address harm reduction in prison in national strategic documents, upon-release interventions appear only in 12. Conclusions: Availability and coverage of harm reduction interventions in European prisons are limited, compared to the community. There is a gap between international recommendations and ‘on-paper’ availability of interventions and their actual implementation. Scaling up harm reduction in prison and throughcare can achieve important individual and public-health benefits.

3 March 2016 in Drugs: Education, Prevention and Policy
Verified
Journal Article
Closed access
PDF file
HSHeino Stöver
Heino Stöver
FHFabienne Hariga
Fabienne Hariga
Aims: In most countries, the spread of HIV and hepatitis C in prisons is clearly driven by injecting drug use with many infected prisoners who are unaware of their infection status. Despite many studies confirming the facts about risk behaviour and the prison setting as a risk environment for maintaining or taking up of risk behaviour, little progress has been made around effective and efficient infectious prophylaxis by means of prison-based needle and syringe programs and associated education. The aim of this contribution is to study why effective and efficient prevention models applied in the community (like PNSP) are very rarely implemented in prison settings. Findings: Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange in prisons. A United Nations Office on Drugs and Crime (UNODC) handbook on the implementation of prison-based needle exchange has been elaborated to better inform and guide officials in the Ministries of Justice, Health and people in charge of healthcare in prisons. It integrates the views and experiences of many experts throughout the world. Conclusions: The key problem apart from political problems in implementing prison-based needle and syringe programmes (PNSP) remains the lack of guarantee of confidentiality to prisoners. This is hindering prisoners from participating in the programmes continuously. The second problem is that HIV/AIDS and opioid consumption are no longer the key drivers of the debate around drugs and infectious diseases in prisons, but instead new psychoactive substances (NPS) and steroids have become issues. In many countries, the HIV rate among drug using prisoners is lower compared 20 years ago (e.g. Western Europe). While hepatitis C is by far the most prevalent infectious disease, it has been neglected by policy makers. It has been difficult to develop momentum to legitimise concerted action to prevent the spread of infectious diseases. The handbook of the UNODC aims to serve as a basis for the implementation of PNSPs.

21 December 2019 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
HSHeino Stöver
Heino Stöver
DJDaniela Jamin
Daniela Jamin
IMIngo Ilja Michels
Ingo Ilja Michels
BKBärbel Knorr
Bärbel Knorr
KKKarlheinz Keppler
Karlheinz Keppler
Daniel DeimelDaniel Deimel
Daniel Deimel
Background: The above-average proportion of people with opioid use disorder living in prisons is a worldwide reality, and the need to treat these people was recognized internationally more than 20 years ago. Studies have shown that substitution therapies are best suited to treat opioid use disorder and reduce the risk of HIV and hepatitis C transmission and overdose. However, huge health inequalities exist in and outside of prison due to the different implementation of opioid substitution therapy (OST). People living in prisons are entitled to the best possible health care. This is established by the Universal Declaration of Human Rights and by the International Convention on Economic, Social and Cultural Rights. Solely the imprisonment, and not the loss of fundamental human rights, constitutes the punishment. Methods: A qualitative literature search using PubMed and Google Scholar was performed in order to identify relevant publications. Results: This review shows the inequality in availability of opioid substitution therapy for people living in prison compared with people outside of prison in Germany. It also gives possible reasons and evidence for this inequality, showing that continuing or initiating OST in prison is more beneficial for the health of people living in prison than abstinence-oriented treatment only. Conclusion: It is important that drug use disorder is treated as a serious illness also in prison. Joint efforts are needed to provide people living in prison with the best possible treatment and to minimize the adverse effects of drug use. Therefore, with laws, policies, and programs that conform to international human rights standards, each state must ensure that people living in prison receive the same health care as people outside of prison.